Irvine-based AcuFocus Inc., developer of an eye implant to correct the inability to focus up close with aging, has received an investment from Bausch & Lomb Inc. as well as an option to be bought.
Terms of the deal weren’t disclosed.
AcuFocus is working on a lens that’s implanted in the cornea to treat presbyopia and reduce dependence on reading glasses. Clinical trials started last year.
“With Bausch & Lomb’s investment, we can accelerate and broaden our efforts to bring this exciting technology to refractive surgeons and their patients,” said Ed Peterson, chief executive of AcuFocus.
In 2005, AcuFocus raised $27.5 million, including from the Newport Beach office of Menlo Park-based Versant Ventures.
Other investors include Carlyle Group LP and Accuitive Medical Ventures LLC.
The study of AcuFocus’ lens is expected to take about three years.
